Cetuximab and panitumumab for previously untreated metastatic colorectal cancer

  • Technology appraisal guidance
  • TA439
  • Published: 
  • Last updated: 
Download guidance (PDF)

1 Recommendations

1.1 Cetuximab is recommended, within its marketing authorisation, as an option for previously untreated epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in adults in combination with:

  • 5‑fluorouracil, folinic acid and oxaliplatin (FOLFOX) or

  • 5‑fluorouracil, folinic acid and irinotecan (FOLFIRI).

1.2 Panitumumab is recommended, within its marketing authorisation, as an option for previously untreated RAS wild-type metastatic colorectal cancer in adults in combination with:

  • FOLFOX or

  • FOLFIRI.

1.3 The drugs are recommended only when the companies provide them with the discount agreed in the patient access scheme (for panitumumab) or commercial access agreement (for cetuximab).